These novel treatments, Semaglutide , represent a groundbreaking advancement in treating obesity and potentially associated conditions . These drugs are categorized as GLP-1 receptor stimulators, meaning these substances to emulate the body's GLP-1 peptide, enhancing glucose production and reduci